VERACYTE INC
Veracyte, Inc. (VCYT) is a diagnostics company focused on genomic and molecular tests that help clinicians make more informed decisions in cancer and other disease pathways. Its test portfolio — including widely cited thyroid and lung classifiers and a prostate genomic tool — aims to reduce unnecessary procedures by improving diagnostic accuracy. Revenue comes largely from test sales, reimbursement from insurers and continued clinical validation. Key growth drivers are wider clinical adoption, expanded indications, and international coverage, while risks include reimbursement changes, competitive innovation, and regulatory or clinical trial setbacks. The company operates in a sector where scale, data and clinician trust matter, and growth often requires heavy investment in R&D and sales infrastructure. This summary is educational and not personalised financial advice — investors should review the latest financial statements and consider their own risk tolerance before acting, as past performance offers no guarantee of future returns.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Veracyte's stock as it is expected to perform well in the near future.
Financial Health
Veracyte is performing well with strong revenue and cash flow, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring VCYT
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Adoption and Revenue
Expanded clinician uptake and broader insurance coverage can drive revenue, though reimbursement shifts may affect results.
International Expansion
Growing presence outside the US can open new markets, but local regulation and payer systems add complexity.
Data and Innovation
Proprietary genomic data and continued R&D can support differentiation, though competitors and tech change pose risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.